Scynexis (SCYX) Non-Current Deffered Revenue (2013 - 2025)
Scynexis' (SCYX) quarterly Non-Current Deffered Revenue came in at $800000.0 in Q3 2025, down 38.46% YoY from $1.3 million in Q3 2024, and up 60.0% on a QoQ basis from $500000.0 in Q2 2025.
Scynexis (SCYX) Non-Current Deffered Revenue (2013 - 2025) Analysis & Trends
Scynexis (SCYX) has 9 years of Non-Current Deffered Revenue data on file, last reported at $800000.0 in Q3 2025.
- Quarterly Non-Current Deffered Revenue fell 38.46% year-over-year to $800000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $800000.0 (down 38.46% YoY) and the FY2024 annual result came in at $1.3 million, down 52.55% from the prior year.
- Non-Current Deffered Revenue climbed to $800000.0 in Q3 2025, from $500000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $2.7 million in Q4 2023 to a low of $500000.0 in Q2 2025.
- A 3-year average of $1.5 million and a median of $1.3 million in 2024 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue soared 59.39% — and 2025, when it slumped 72.48%.
- Tracing SCYX's Non-Current Deffered Revenue over 3 years: stood at $2.7 million in 2023, then sank by 52.55% to $1.3 million in 2024, then sank by 38.18% to $800000.0 in 2025.
- The last three Non-Current Deffered Revenue figures came in at $800000.0 (Q3 2025), $500000.0 (Q2 2025), and $1.3 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Scynexis | 61.90 Mn | -52.80 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 1.29 Mn |
| Dec 31, 2024 | 1.29 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | 2.10 Mn |
| Dec 31, 2023 | 2.73 Mn |
| Sep 30, 2023 | 1.65 Mn |
| Jun 30, 2023 | 1.14 Mn |
| Mar 31, 2018 | 57,000.00 |
| Dec 31, 2017 | 121,000.00 |
| Jun 30, 2017 | 249,000.00 |
| Mar 31, 2017 | 20,000.00 |
| Dec 31, 2016 | 25,000.00 |
| Sep 30, 2016 | 442,000.00 |
| Jun 30, 2016 | 25,000.00 |
| Mar 31, 2016 | 571,000.00 |
| Dec 31, 2015 | 25,000.00 |
| Sep 30, 2015 | 699,000.00 |